Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1238219 | 0.85 | CA2 (0.48) | CA2CA12CA1CA9CA14 | |
| SCHEMBL769777 | 0.84 | NAPRT (0.46) | TBXAS1HTTPLA2G7CYP11B1CYP11B2 | |
| SCHEMBL4662891 | 0.82 | CA2 (0.47) | CA2CA12CA1CA9CA14 | |
| SCHEMBL407413 | 0.81 | CA2 (0.50) | CA2CA12CA1CA9CA14 | |
| SCHEMBL30988956 | 0.81 | CA2 (0.50) | CA2CA12CA1CA9CA14 | |
| Hydrochloric Acid SCHEMBL3517386 | 0.80 | CA1 (0.49) | CA2CA12CA1CA9CA14 | |
| Methane SCHEMBL28850761 | 0.80 | CA2 (0.49) | CA2CA12CA1CA9CA14 | |
| SCHEMBL5510242 | 0.77 | CA2 (0.62) | CA2CA12CA1CA9HTT | |
| Hydrochloric Acid SCHEMBL6177188 | 0.77 | HRH4 (0.49) | TBXAS1HTTCHRNA7PLA2G7CYP11B1 | |
| SCHEMBL21387052 | 0.75 | HSPA5 (0.54) | TBXAS1HTTCHRNA7CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110339829-A | Using aminobenzene (sulphur) amide pyridine as the chromatography media of functional ligand | 浙江大学 | 2019-10-18 | — | — | CN | claimed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | NEITZEL MARTIN | 2011-09-01 | — | — | US | disclosed |
| US-7939657-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | CA2 3100/4885CA12 3906/4885CA1 839/4885 |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | ADORA2B, ADORA2A, ADORA3 | CA2 1890/4885CA12 4577/4885CA1 4388/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | CA2 3239/4885CA12 2707/4885CA1 591/4885 |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | CA2 3239/4885CA12 2707/4885CA1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.